Psychiatric NP Scope of Practice for General Psychiatry

If you’re a psychiatrist or psychiatric nurse practitioner exploring telepsychiatry, you’ve probably asked yourself: Can I legally prescribe Adderall for ADHD over video? What about benzos for anxiety? Do I need to see patients in person first?

The short answer as of early 2026: Yes, you can prescribe controlled substances via telehealth—but the rules are changing, and they vary significantly by state.

Here’s what you need to know to stay compliant while building your telepsychiatry practice.

The Current Reality: Temporary Flexibilities Extended Through 2026

Since March 2020, federal COVID-era telehealth waivers have allowed psychiatrists and PMHNPs to prescribe Schedule II–V controlled substances to new patients after a video evaluation—no in-person visit required. This waiver was supposed to end when the public health emergency expired, but here’s the critical update:

The DEA and HHS extended these telehealth flexibilities through December 31, 2026 (HHS Press Release, January 2, 2026).

This means you can continue prescribing stimulants (Adderall, Ritalin), benzodiazepines (Xanax, Klonopin), and other controlled medications via telehealth to new patients without an initial in-person exam—at least through the end of 2026.

But don’t get too comfortable. The DEA is finalizing permanent rules that will likely require either:

• An in-person visit at some point in the treatment relationship, OR
• A special ‘telemedicine prescriber registration’ for qualified specialists

More on that below.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What the DEA’s Proposed Permanent Rules Mean for Psychiatrists

In January 2025, the DEA unveiled three proposed rules to replace the temporary COVID waivers (DEA Press Release, January 16, 2025). Here’s what matters for general psychiatry:

1. Special Telemedicine Registration for Schedule II Prescribing

The DEA is creating a new pathway: board-certified psychiatrists will be able to obtain a ‘Special Telemedicine Registration’ that allows prescribing Schedule II controlled substances (stimulants, etc.) to new patients via telehealth—without ever requiring an in-person visit.

This is huge. It formally recognizes that mental health providers can safely manage medications like Adderall in a telehealth-only model.

Who qualifies? Initially, the special registration for Schedule II will be limited to:

• Psychiatrists
• Hospice/palliative care physicians
• Long-term care facility physicians
• Pediatricians (for specific uses)

For Schedule III–V substances, any qualified prescriber can apply for the special registration.

The catch: Telehealth platforms themselves will be required to register with the DEA for the first time, and a national Prescription Drug Monitoring Program (PDMP) will be implemented to track prescriptions across state lines.

Timeline: These rules are still in the proposal stage. Implementation could happen in late 2026 or 2027.

2. Buprenorphine Exception: Six Months Before In-Person Required

For addiction psychiatrists: the DEA is proposing to allow six months of buprenorphine treatment via telehealth (including audio-only) before requiring an in-person visit. After 180 days, patients would need to see a provider in person to continue treatment.

This balances access with oversight—especially important given the opioid crisis.

3. If You’ve Seen the Patient In-Person Before, You’re Clear

Here’s a simple rule that won’t change: If a patient has ever been seen in person by you or another provider in your practice, there’s no federal telehealth restriction on prescribing controlled substances.

The Ryan Haight Act’s in-person requirement only applies to new patients who have never had a qualifying medical evaluation.

State Laws: Where Things Get Complicated

Federal law sets the floor, but states can impose stricter rules—and many do. Here’s what you need to know for the six largest telepsychiatry markets:

Florida: Psychiatric Carve-Out Saves the Day

Florida law prohibits prescribing Schedule II controlled substances via telehealth—with a critical exception: it’s allowed for psychiatric treatment (also inpatient, hospice, and nursing home care).

Translation: You can prescribe Adderall for ADHD or Ritalin for psychiatric conditions via telehealth in Florida. You cannot prescribe Schedule II opioids for chronic pain remotely.

Other Florida rules:

• Out-of-state providers can register as ‘Florida Telehealth Providers’ to treat Florida patients without a full Florida license—but you’re still bound by Florida’s prescribing rules
• You must check Florida’s PDMP (E-FORCSE) before prescribing any controlled substance to patients age 16+
• PMHNPs in Florida always require a supervising physician (no independent practice for psych NPs)

(Florida Statutes §456.47)

Texas: MDs Yes, NPs No (for Schedule II)

Texas allows telehealth prescribing of controlled substances under federal law, but with a significant twist: Nurse practitioners and PAs in Texas cannot prescribe Schedule II controlled substances outside of hospital or hospice settings.

This means:

• A Texas psychiatrist can prescribe Adderall via telehealth to outpatients
• A Texas PMHNP cannot—those patients must be seen by a physician for Schedule II prescriptions

Texas also prohibits telehealth prescribing of controlled substances for chronic pain management unless an in-person evaluation has occurred (this mainly affects pain clinics, not psychiatry).

Compliance requirements:

• Mandatory Texas PDMP check before prescribing opioids, benzos, barbiturates, or carisoprodol
• Real-time audio-video required (no telephone-only for new patients)

(Texas Medical Board FAQs)

California: Telehealth-Friendly, But Strict on Monitoring

California doesn’t impose additional telehealth prescribing restrictions beyond federal law. You can prescribe controlled substances via video evaluation if you meet the standard of care.

Key requirements:

• Mandatory CURES PDMP check before first prescribing any Schedule II–IV controlled substance, and every four months during ongoing treatment
• 100% e-prescribing required (since January 2022)
• PMHNPs: California is transitioning to full practice authority. Experienced NPs (3+ years in supervised settings) can now apply for independent practice licenses starting in 2024–2026

(California Medical Board Newsletter)

New York: PDMP Every Time

New York allows telehealth prescribing with no state-specific in-person requirement. The state’s I-STOP law, however, is one of the strictest in the nation:

You must check New York’s Prescription Monitoring Program (PMP) before every prescription of Schedule II, III, or IV controlled substances.

That’s not just the first time—it’s every refill for stimulants, benzos, etc.

Also:

• All prescriptions (controlled and non-controlled) must be sent electronically
• PMHNPs with 3,600+ clinical hours can practice independently and prescribe controlled substances without physician oversight

(NY State Office of Professions Telepractice Guidance)

Pennsylvania: Follow Standard of Care

Pennsylvania hasn’t enacted a comprehensive telehealth law yet, but the state medical board allows telehealth prescribing as long as you meet the standard of care.

Key points:

• Mandatory PDMP check before prescribing opioids or benzos (and periodically during treatment)
• E-prescribing required for controlled substances (since 2019)
• PMHNPs must have a collaborative agreement with at least two physicians for prescriptive authority
• Schedule II prescriptions by NPs limited to 30-day supply

(PA Code §21.285a – CRNP Collaborative Agreements)

Illinois: Full Practice for Experienced NPs

Illinois allows telehealth prescribing in line with federal law. The state offers full practice authority for experienced PMHNPs (4,000 clinical hours + extra training), but with a quirk:

Even independent NPs must have a physician ‘consultation relationship’ to prescribe benzodiazepines or Schedule II opioids, limited to 30-day supplies.

This may or may not apply to Schedule II stimulants (the law is somewhat ambiguous), but it’s worth confirming with the Illinois Department of Financial and Professional Regulation.

Other requirements:

• Mandatory ILPMP check before prescribing opioids
• E-prescribing required for controlled substances (since January 2023)

(Illinois Nurse Practice Act – 225 ILCS 65)

Psychiatrist vs. PMHNP: Scope of Practice Differences

Psychiatrists (MD/DO): Full prescriptive authority in all states. You can prescribe any controlled substance within your scope of practice. The only limits are federal DEA rules and state-specific telehealth restrictions (like Florida’s chronic pain ban).

PMHNPs: Your authority depends entirely on state law.

• Full practice states (New York, California starting 2024–26, Arizona, Washington): You can prescribe independently, including controlled substances, after meeting experience requirements
• Reduced practice states (Pennsylvania, Ohio, Utah): You need a physician collaboration agreement but can prescribe with that in place
• Restricted practice states (Texas, Florida, South Carolina): You must work under physician supervision, and some states prohibit NPs from prescribing Schedule II at all (e.g., Texas)

If you’re a PMHNP joining a telehealth platform, know your state’s rules. Some platforms provide supervising physicians; others only hire independent NPs.

(Tebra: State-by-State NP Practice Authority Laws)

Compliance Checklist: What You Must Do

Regardless of your state, follow these steps to stay compliant:

1. Verify you’re licensed in the state where the patient is located. Telehealth is considered to occur where the patient sits, not where you sit.

2. Check your state’s PDMP before prescribing controlled substances (mandatory in most states).

3. Use e-prescribing for controlled substances (required in nearly all states).

4. Document thoroughly. Your telehealth evaluation should be as comprehensive as an in-person exam—history, mental status, treatment plan, informed consent.

5. Use secure, HIPAA-compliant video platforms. Audio-only is generally not sufficient for initial evaluations involving controlled substances (exception: buprenorphine for OUD in some cases).

6. Complete the 8-hour DEA training on substance use disorder and pain management if you haven’t already (required for all DEA renewals since 2023).

7. Stay updated on DEA rule changes. When the permanent rules are finalized (likely late 2026), you may need to obtain a special telemedicine registration or adjust your practice protocols.

(SAMHSA: MAT Act Waiver Elimination and Training Requirements)

Why This Matters for Your Practice Economics

Let’s talk business for a moment.

If you’re trying to build a telepsychiatry practice by marketing yourself—whether through SEO, Google Ads, or directory listings like Psychology Today—you’re looking at a patient acquisition cost of $200–500+ per qualified patient when you factor in:

• Monthly ad spend (Google Ads for ‘online psychiatrist’ or ‘ADHD evaluation’ can run $15–40 per click, with most clicks not converting)
• Agency or consultant fees for SEO and PPC management
• Staff time to handle and qualify leads
• No-show rates from cold leads
• 6–12 months before SEO generates meaningful patient flow

And that’s if you have the expertise and budget to run effective campaigns.

Telehealth platforms like Klarity Health flip this model: You pay a standard fee per new patient lead (similar to Zocdoc’s per-booking model), but only when a pre-qualified patient books with you.

No upfront marketing spend. No wasted ad budget. No gambling on whether your SEO will rank in six months.

You also get:

• Built-in telehealth infrastructure (no need to pay for a separate platform)
• Compliance support (someone else tracks state licensing requirements and rule changes)
• Both insurance and cash-pay patient flow
• Control over your schedule—you only pay when you see patients

The economic comparison is simple: Would you rather spend $3,000–5,000/month on marketing with uncertain ROI, or pay only when a qualified patient shows up ready to start treatment?

For most providers—especially those starting out or scaling beyond their current patient base—platforms that handle patient acquisition remove the risk entirely.

FAQs

Q: Can I prescribe Adderall via telehealth to a new patient in 2026?
A: Yes, under current federal law (extended through December 31, 2026). Make sure you’re licensed in the patient’s state and follow that state’s rules (e.g., Florida’s psychiatric exception, Texas’s MD-only rule for Schedule II).

Q: Do I need to see patients in person at some point?
A: Not yet under federal law. But DEA’s proposed permanent rules may require an in-person visit or a special telemedicine registration. Stay tuned for final rules expected in late 2026.

Q: Can PMHNPs prescribe controlled substances independently?
A: It depends on the state. In New York and California (post-2026), yes if you meet experience requirements. In Texas and Florida, no—you need physician supervision.

Q: What happens if the DEA doesn’t finalize the permanent rules by 2027?
A: The DEA and HHS could extend the temporary flexibilities again (they’ve done it four times already). But providers should plan for eventual changes—either in-person requirements or special registration.

Q: Can I prescribe buprenorphine for opioid use disorder via telehealth?
A: Yes. The X-waiver was eliminated in 2023, so any DEA-registered prescriber can prescribe buprenorphine. The DEA’s proposed rule would allow six months of telehealth treatment (including audio-only) before requiring an in-person visit.

Q: Do I need malpractice insurance for telehealth?
A: Yes. Make sure your policy covers telehealth and extends to all states where you treat patients.

The Bottom Line

Prescribing controlled substances via telehealth is legal and will remain so through at least the end of 2026. But the regulatory landscape is shifting, and state laws add layers of complexity.

What psychiatrists and PMHNPs need to do now:

1. Understand your state’s specific rules (use the state-by-state table above as a starting point)
2. Stay compliant with PDMP checks, e-prescribing, and documentation standards
3. Watch for DEA’s final rules on special telemedicine registration
4. If you’re building a telepsychiatry practice, consider whether DIY marketing makes financial sense—or if joining a platform that handles patient acquisition is the smarter move

The demand for telepsychiatry isn’t going away. Patients want access to psychiatric care without driving an hour to a clinic. Employers and insurers want cost-effective solutions. And providers want flexibility and better income.

The providers who succeed will be those who navigate the regulations confidently and focus on delivering great care—not getting lost in the weeds of marketing and compliance.

Ready to explore a smarter way to grow your telepsychiatry practice? Join Klarity Health’s provider network and let us handle patient acquisition while you focus on what you do best: treating patients.

Sources and Citations

1. U.S. Department of Health and Human Services (HHS). ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration (DEA). ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Critical Care While Implementing Patient Protections.’ Press Release, January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Legislature. Florida Statutes §456.47: ‘Use of Telehealth to Provide Services.’ 2025 Edition. http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Texas Medical Board. ‘Prescriptive Authority and Supervision FAQs.’ Updated 2024. https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

5. Substance Abuse and Mental Health Services Administration (SAMHSA). ‘MAT Act Waiver Elimination and New Training Requirements.’ Updated 2023. https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Telehealth and controlled substance prescribing laws are subject to change. Providers should consult their state medical board, legal counsel, and DEA resources for the most current requirements.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices